Atlas Trials

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

Clinical trial NCT06255626 · RECRUITING

Trial details

NCT number
NCT06255626
Sponsor
ANRS, Emerging Infectious Diseases
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2024-05-27
Primary completion
2025-09-01
Enrollment
215

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.